Publication
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
Hiroto Hatano, Tatsuya Yoshida, Ryoko Inaba Higashiyama, Masayuki Shirasawa, Yoshiro Nakahara, Katsuhiko Naoki, Hiroshi Nokihara, Kentaro Gosho, Yuji Uehara, Yukio Hosomi, Ayu Kiritani, Hiroshi Wakui, Yuki Shinno, Yusuke Okuma, Hidehito Horinouchi, Noboru Yamamoto, Yasushi Goto
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Epidermal growth factor receptor (EGFR) exon 19 deletion subtypes may be associated with differential survival outcomes following EGFR-tyrosine kinase inhibitor treatment. However, evidence remains scarce, particularly regarding osimertinib, and the underlying biological mechanisms are…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available